Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: A single-center experience

Clinical Transplantation

Volumn 27, Issue 4, 2013, Pages 546-554

  Moscarelli, Luciano ^a   Caroti, Leonardo ^a   Antognoli, Giulia ^a   Zanazzi, Maria ^a   Di Maria, Lorenzo ^a   Carta, Paolo ^a   Minetti, Enrico ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

BK virus; Everolimus; Interstitial nephritis; Kidney transplantation; Mycophenolic acid; Polyomavirus

Indexed keywords

ACICLOVIR; BASILIXIMAB; COTRIMOXAZOLE; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; NYSTATIN; STEROID; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; POLYOMA VIRUS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIREMIA; VIRUS DETECTION; VIRUS LOAD;

BK VIRUS; EVEROLIMUS; INTERSTITIAL NEPHRITIS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; POLYOMAVIRUS;

ADULT; AGED; AGED, 80 AND OVER; BK VIRUS; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POLYOMAVIRUS INFECTIONS; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; SIROLIMUS; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 84881548952     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12151     Document Type: Article

References (31)

1. Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis 2003: 3: 611.
2. Hirsch HH, Brennan DC, Drachenberg CB et al. Polyomavirus associated-nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 2005: 79: 1277.
3. Trofe J, Hirsch HH, Ramos E. Polyomavirus-associated nephropathy: update of clinical management in kidney transplant patients. Transpl Infect Dis 2006: 8: 76.
4. Mayr M, Nickeleit V, Hirsch HH et al. Polyomavirus BK nephropathy in a kidney transplant recipient: critical issues of diagnosis and management. Am J Kidney Dis 2001: 38: E13.
5. Nickeleit V, Klimkait T, Binet IF et al. Testing for polyomavirus type BKDNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 2000: 342: 1309.
6. Hirsch HH, Mohaupt M, KlimKait T. Prospective monitoring of BK virus load after discontinuing sirolimus treatment in a renal transplant patient with BK virus nephropathy. J Infect Dis 2001: 184: 1494.
7. Wali RK, Drachenberg C, Hirsch HH et al. BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation 2004: 78: 1069.
8. Benavides CA, Pollard VB, Mauiyyedi S et al. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 2007: 84: 83.
9. Brennan DC, Legendre C, Patel D et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant 2011: 11: 2453.
10. Kasiske BL, Valquez MA, Harmon WE et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 2000: 11: S1.
11. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
12. Drachenberg CB, Papadimitriou JC, Hirsch HH et al. Histological patterns of Polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant 2004: 4: 2082.
13. Araki K, Turner AP, Shaffer VO et al. mTOR regulates memory CD8 cell differentiation. Nature 2009: 460: 108.
14. Ferrer IR, Wagener ME, Robertson JM et al. Cutting edge: rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J Immunol 2010: 185: 2004.
15. Sabatini DM, Erdjument-Bromage H, Lui M et al. A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994: 78: 35.
16. Kovarik JM. Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction. Drugs Today (Barc) 2004: 40: 101.
17. Lane HA, Wood JM, McSheehy PM et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009: 15: 1612.
18. McCabe MT, Low JA, Imperiale MJ et al. Human polyomavirus BK virus transcriptionally activates DNA methyltransferase 1 through the pRb/E2F pathway. Oncogene 2006: 25: 2727.
19. Liacini A, Seamone ME, Muruve D et al. Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation 2010: 90: 1450.
20. Bennet W. Immunosuppression with mycophenolic acid: one size does not fit all. J Am Soc Nephrol 2003: 14: 2414.
21. Brennan DC, Agha I, Bohl DL et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005: 5: 582.
22. Nickeleit V, Mihatsch MJ. Polyomavirus nephropathy in native kidneys and renal allografts: an update on an escalating threat. Transpl Int 2006: 19: 960.
23. Ginevri F, Azzi A, Hirsch HH et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007: 7: 2727.
24. Knowles WA. The epidemiology of BK virus and the occurrence of antigenic and genomic subtypes. In: Khalili K, Stoner GL, eds. Human Polyomaviruses: Molecular and Clinical Perspectives. New York: Wiley-Liss, 2001: 527.
25. Randhawa PS, Gupta G, Vats A et al. Immunoglobulin G, A, and M responses to BK virus in renal transplantation. Clin Vaccine Immunol 2006: 13: 1057.
26. Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 2000: 47: 63.
27. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991: 33: 175.
28. Salvadori M, Scolari MP, Bertoni E et al. Everolimus with very low-exposure cyclosporine A in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 2009: 88: 1194.
29. Hirsch HH, Vincenti F, Friman S et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicentre study. Am J Transplant 2013: 13: 136.
30. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998: 338: 1813.
31. Burlingham WJ, Grailer AP, Hullett D et al. Inhibition of both MLC and in vitro IgG memory response to tetanus toxoid by RS-61443. Transplantation 1991: 51: 545.